MDxHealth nieuws 2014

1. [verwijderd] 28 april 2014 09:50

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   www.mdxhealth.com/images/documents/we...
   
   Hier kan je toch ook al gigantisch veel info uithalen !
   Alleen zou ik graag meer info zien mbt de licenties die al afgeven zijn (ala ExactScience) . Hoe staan daar de ontwikkelingen ? Wannneer kunnen we daar meer info over verwachten (vooruitgang)
2. [verwijderd] 28 april 2014 09:58

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Wanneer in mei komt de newsletter en de update?
3. [verwijderd] 28 april 2014 10:06

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   tsete schreef op 28 april 2014 09:58:

   Wanneer in mei komt de newsletter en de update?
   

   Waarom wil je dat weten Diegy ?
4. [verwijderd] 28 april 2014 10:10

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Diegy?
5. [verwijderd] 28 april 2014 10:16

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Ja
6. [verwijderd] 28 april 2014 10:38

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Ge zit er volledig naast makker
7. peebee 28 april 2014 11:11

   auteur info

   • peebee

     Lid sinds: 16 nov 2009

     Laatste bezoek: 27 feb 2025

   • Aanbevelingen

     Ontvangen: 115

     Gegeven: 41

   •    Aantal posts: 1.728

   newsletter is bevestigd vanuit MDX, deze komt in mei (exacte datum nog onbekend)
   Update komt 8 mei.
   
   Ik neem aan dat tussen deze 2 behoorlijk wat dagen zitten, anders dreigt een overlapping van info.
   
   Dit betekent dat de newsletter meteen in mei komt (deze week nog) en anders pas eind mei.
   
   
8. [verwijderd] 28 april 2014 11:18

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   thx peebee
9. Pelikapuntzak 28 april 2014 11:26

   auteur info

   • Pelikapuntzak

     Lid sinds: 18 sep 2011

     Laatste bezoek: 05 feb 2025

   • Aanbevelingen

     Ontvangen: 278

     Gegeven: 149

   •    Aantal posts: 2.135

   quote:

   tsete schreef op 28 april 2014 09:58:

   Wanneer in mei komt de newsletter en de update?
   

   Kwartaalcijfers op 6 mei as. met outlook cq update.
10. Pelikapuntzak 28 april 2014 12:50

    auteur info

    • Pelikapuntzak

      Lid sinds: 18 sep 2011

      Laatste bezoek: 05 feb 2025

    • Aanbevelingen

      Ontvangen: 278

      Gegeven: 149

    •    Aantal posts: 2.135

    Voor dit bizar laag volume moeten we ver teruggaan in de tijd. Nog geen 10K.?????. Er zullen forumleden zijn die er meer in portefeuille hebben.
11. Pelikapuntzak 28 april 2014 13:04

    auteur info

    • Pelikapuntzak

      Lid sinds: 18 sep 2011

      Laatste bezoek: 05 feb 2025

    • Aanbevelingen

      Ontvangen: 278

      Gegeven: 149

    •    Aantal posts: 2.135

    Overwegend groen op de beurzen. 'T is niet altijd feest voor MDx. Vandaag alleen maar verkopen.
12. [verwijderd] 28 april 2014 13:43

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Heeft er iemand veel tijd ?
    
    Gaarne googlen naar info over onderstaande licenties bij deze bedrijven/licentienemers van MDX (EXAXT SCIENCE inmiddels bekend)
    Bij de overige bedrijven moet toch ook iets moois uit te halen zijn .
    Zitten een paar hele grote vissen tussen ( Pfizer/GSK /Johnson Johnson/
    
    Existing Out-licensing and Partners Deals
    Company Product / Area
    Exact Sciences DNA Methylation for stool-based colorectal cancer screening
    Johnson&Johnson Certain screening applications
    LabCorp MGMT and prostate tissue
    Millipore Merck Serono DNA Methylation for research market
    Qiagen DNA Methylation for research market
    Takara DNA Methylation for research market
    Self-Screen Cervical cancer triage for HPV-positive and inconclusive-Pap women
    Pfizer Development of Companion Dx for Parp inhibitor
    GlaxoSmithKline Development of Companion Dx for lung cancer
    TEVA Pharmaceuticals Commercialization of ConfirmMDx for Prostate Cancer and PredictMDx for Glioblastoma tests in Israel
    Sumitomo Coporation Provide companion diagnostic solutions or theranostics to pharmaceutical companies in Japan
13. [verwijderd] 28 april 2014 13:45

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Pelikapuntzak schreef op 28 april 2014 12:50:

    Voor dit bizar laag volume moeten we ver teruggaan in de tijd. Nog geen 10K.?????. Er zullen forumleden zijn die er meer in portefeuille hebben.
    

    Mijn hoeveelheid onveranderd .
    
    Koers wordt gedrukt met lage aantallen en grote blokken zetten in de hoop dat stukjes ingeleverd gaan worden .
    Hebben we vaker gezien en dan ging het meestal kort daarna omhoog . Hopelijk weer hetzelfde ritueel.
14. Pelikapuntzak 28 april 2014 14:11

    auteur info

    • Pelikapuntzak

      Lid sinds: 18 sep 2011

      Laatste bezoek: 05 feb 2025

    • Aanbevelingen

      Ontvangen: 278

      Gegeven: 149

    •    Aantal posts: 2.135

    quote:

    bioscience schreef op 28 april 2014 13:45:

    [...]
    
    Mijn hoeveelheid onveranderd .
    
    Koers wordt gedrukt met lage aantallen en grote blokken zetten in de hoop dat stukjes ingeleverd gaan worden .
    Hebben we vaker gezien en dan ging het meestal kort daarna omhoog . Hopelijk weer hetzelfde ritueel.
    

    Er wordt alleen maar verkocht in minimale aantallen. Amper iets uit de laat gehaald. Was vrijdag ook al zo. Verhouding 25/75 en toch maar een relatief kleine daling.
    
    Googlen om meer informatie heeft tot nu toe niets opgeleverd............altijd weer een doorverwijzing naar bekende informatie. Dat zit behoorlijk op slot.
15. [verwijderd] 28 april 2014 14:16

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Onderhandse handel suggereert verschuiving bij grote aandeelhouders. Hoewel Exact nog geen cashflow produceert voor MDX zien eigen verwachtingen er zeer goed uit! Kleine aandelen flow gaat in de toekomst werken als een katalysator met een koersdoel van 6,70. Met lange termijn visie van de Meulemeester Capital Investments naar de 8. Een BAH advies wordt nog steeds gehanteerd.
16. [verwijderd] 28 april 2014 14:27

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Bij Exact Science heeft de ontwikkeling ook heel wat jaren geduurd tot het succes van nu
    
    Oude persbericht Labcorp . Toen werd de deal nog gesloten met de oude MDX naam (oncomethylome )
    Deal van 2008 . Zou best binnekort wel eens uit kunnen gaan rollen als we naar Exact Science termijn kijken .
    
    Press Release
    Methylation Assay for Colorectal Cancer Screening Launched by LabCorp
    
    OncoMethylome's methylation detection technology is used in the new ColoSureTM colorectal cancer screening assay
    
    Liege (Belgium) - July 15, 2008, 08:00 CET - OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announced today that Laboratory Corporation of America® Holdings (LabCorp®) launched ColoSureTM, a stool-based testing service for colorectal cancer screening which is included in the American Cancer Society's colorectal cancer screening guidelines. The testing service is carried out with reagents for detecting methylation of the Vimentin DNA marker with Methylation-Specific PCR (MSP) technology. As announced in a press release dated June 23, 2008, OncoMethylome earns revenue for supplying LabCorp with these reagents and qualifies for milestones tied to commercial uptake of the reagents by LabCorp.
    
    "This is the second methylation assay launched by LabCorp in 2008. We are pleased with LabCorp's commitment to make OncoMethylome's methylation technology available to patients. We hope this test, for colorectal cancer screening, will help to detect colorectal cancer that would otherwise have been undetected and untreated" commented Herman Spolders, CEO of OncoMethylome.
    
    To download this press release as a PDF, click here: Press Release PDF
    
    About Colorectal Cancer
    Colorectal cancer is a very common illness with more than 900,000 new cases and 500,000 deaths recorded worldwide each year. Colorectal cancer is best treatable if diagnosed early; however, today, fewer than 40% of colorectal cancers are detected early. American Cancer Society estimates that 50% of deaths from colorectal cancer could be prevented if everyone above the age of 50 were screened regularly. In Europe and US, there are over 200 million people over the age of 50 who would benefit from regular screening for colorectal cancer. OncoMethylome is developing sensitive and non-invasive stool and blood screening tests for this disease.
    
    About Methylation and Methylation Markers
    Methylation is a natural control mechanism that regulates gene expression in DNA. Abnormal methylation of certain genes, such as tumor suppressor genes, can silence gene expression and is associated with cancer development. Genes, whose methylation is linked to cancer, are called methylation markers. OncoMethylome owns proprietary technology that is highly sensitive and capable of detecting methylation markers, and thereby cancer, even in early stages of cancer development. In the case of colorectal cancer, this technology identifies methylation of genes, or methylation markers, that have been shown to be associated with colorectal cancer.
    
    About OncoMethylome Sciences
    OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is a molecular diagnostics company developing gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company's tests are designed to help the physician (i) accurately detect cancer in early stages of cancer development, (ii) predict a patient's response to drug therapy, and (iii) predict the likelihood of cancer recurrence.
    
    OncoMethylome boasts a broad product development pipeline consisting of ten products and a solid partnering record. The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with Veridex LLC, a Johnson & Johnson company, LabCorp, Schering-Plough Corp., GlaxoSmithKline Biologicals, Abbott, Merck KGaA, Millipore Corporation's BioScience Division, and EXACT Sciences Corp. OncoMethylome's products are based on methylation technology invented by Johns Hopkins University (USA).
    
    Established in January 2003, OncoMethylome has offices in Liege and Leuven (Belgium), in Durham, NC (USA), and in Amsterdam (the Netherlands).
    
17. [verwijderd] 28 april 2014 14:33

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Pfizer licentie
    
    GEN News HighlightsMore »
    Jan 31, 2011
    MDxHealth to Develop Companion Diagnostic for Pfizer Cancer Candidate
    MDxHealth is to work with Pfizer, Newcastle University (UK) and Cancer Research Technology (CRT; the tech transfer arm of Cancer Research UK), to identify and develop a biomarker test for predicting breast and ovarian cancer patients’ responses to its three partners’ Phase II-stage PARP inhibitor candidate PF-01367338 (formerly AG-14699).
    
    PF-01367338 is an inhibitor of both the PARP1 and PARP2b enzymes, which are involved in cellular DNA damage repair. The biomarker assay collaboration will involve MDxHealth profiling the methylation patterns of DNA damage repair genes to identify those involved in predicting tumor development and response to PARP inhibition.
    
    The firm aims to set up a high-throughput platform that is clinically validated to test for epigenetic defects in DDR genes for use in clinical trials. MDxHealth says under terms of the deal with Pfizer, Newcastle University, and CRT, it will retain the rights to any resulting methylation-based commercial companion diagnostic.
    
    MDxHealth is exploiting its DNA-based methylation technology to develop and commercialize molecular diagnostic products for personalized cancer treatment. The firm is developing clinical diagnostics for use by physicians in the assessment of cancer diagnosis and prognosis and is working with pharmaceutical industry partners to develop pharmaco-diagnostics that could be used to select in conjunction with clinical trials and the regulatory approval process.
18. [verwijderd] 28 april 2014 14:34

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    GSK license ( 2010 /oncomety.)
    
    Press Release
    OncoMethylome Sciences Signs Agreement for the Potential use of its technology platform in GlaxoSmithKline Biologicals Immunotherapy Development Program
    
    DURHAM, the United States, and LIEGE, BELGIUM - September 23rd, 2010 - OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA), a leading molecular diagnostics company, announced today that it has entered into an agreement with GlaxoSmithKline Biologicals S.A. (GSK) for the potential use of one of its DNA methylation specific PCR biomarkers in GSKs immunotherapy development program. Additional financial details were not disclosed.
    
    OncoMethylome's biomarker is stable, highly accurate, and, unlike many other biomarkers, allows for the analysis of non-invasive tissue samples.
    
    "We are very pleased to enter into this agreement with GSK. This project was initiated in 2007 and is a prime example of how we can bring our considerable regional strengths to bear on global healthcare issues," said Jan Groen, Ph.D., Chief Executive Officer of OncoMethylome. "Furthermore, this agreement marks an important step for our company in the use of our biomarker with certain immunotherapeutics in development by GSK, and underpins our strategy of leveraging our methylation specific PCR platform in the rapidly emerging field of companion diagnostics and personalized medicine."
    
    About OncoMethylome Sciences
    OncoMethylome Sciences is a leading molecular diagnostics company that commercializes and develops tests to assist physicians in detecting and treating cancer. The company's tests are based on proprietary gene methylation technology and are designed to help the physician accurately detect early stages of cancer, predict a patient's response to drug therapy, and predict the likelihood of cancer recurrence. OncoMethylome Sciences collaborates with leading cancer research centers, such as Johns Hopkins, in Baltimore, MD, and has a number of commercial and collaborative partnerships with LabCorp, Schering-Plough, GlaxoSmithKline Biologicals, Roche, Merck Serono and Qiagen.
    
    For more information:
    Dr. Jan Groen
    CEO
    Telephone (+32) 4.364.20.70
    
    This press release contains forward-looking statements and estimates with respect to the anticipated future performance of OncoMethylome and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company's control, and may turn out to be materially different. OncoMethylome expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.
    
    English version
    
    
19. [verwijderd] 28 april 2014 14:37

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Theva Pharma license ( redelijk recent)
    
    Press Release
    MDxHealth Announces Agreement with Teva Pharmaceuticals for Commercialization of Two Cancer Tests in Israel
    
    
    ConfirmMDx for Prostate Cancer and PredictMDx for Glioblastoma Made Available Through Teva's Extensive Oncology Network
    
    IRVINE, CA, and HERSTAL, BELGIUM - 8:00 AM, January 23, 2014 MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has signed an exclusive agreement with Teva Pharmaceuticals Ltd. for commercialization of ConfirmMDx® for Prostate Cancer and PredictMDx® for Glioblastoma tests in Israel. ConfirmMDx provides physicians with actionable information that helps improve patient care, particularly the avoidance of unnecessary repeat prostate biopsies. The PredictMDx test is used to identify glioma patients who have methylation of the MGMT (O6-Methylguanine-DNA Methyltransferase) gene. In clinical studies, these patients have shown the potential to respond better to certain chemotherapeutic drugs.
    
    "This partnership with Teva means that these important tests will now become available to cancer patients in Israel, our second market after the U.S.," said Dr. Jan Groen, CEO of MDxHealth. "We are delighted that Teva has agreed to invest its significant commercialization resources into our unique cancer products, expanding access to a new and diverse patient population."
    
    Under the terms of this three-years agreement, Teva Pharmaceuticals Industries will be the exclusive distributor of both tests in Israel. Samples will be sent to MDxHealth's CLIA-registered laboratory in Irvine, California for analysis. Teva will reimburse MDxHealth for all the testing services.
    
    About ConfirmMDx® for Prostate Cancer
    
    Over 975,000 American men are diagnosed with a negative prostate biopsy each year; however approximately 25-35% of those men receive false-negative results. Under the current standard of care, prostate biopsy procedures consisting of 10-12 needle biopsy cores only sample approximately 1% of a man's prostate. This approach leaves men at risk of occult cancer, leading to a high rate of repeat biopsies, often on cancer-free men. There is an unmet medical need for a clinically effective diagnostic test to address this dilemma. ConfirmMDx for Prostate Cancer is able to detect an epigenetic field effect or 'halo' associated with the cancerization process at the DNA level. This "halo" around a cancer lesion can be present despite cells having a normal appearance under the microscope. Thus ConfirmMDx for Prostate Cancer aids urologists in identifying truly negative men who may forego an unnecessary repeat biopsy procedure.
    
    About PredictMDx® for Glioblastoma
    
    MDxHealth's PredictMDx for Glioblastoma (MGMT) test provides actionable information to oncologists seeking to provide personalized treatment of patients with brain cancer. The test assesses the methylation status of the MGMT gene, which is crucial to promoting DNA repair. If the MGMT gene is methylated, cancer patients have shown improved response to alkylating drug therapy. Studies on thousands of patients have shown that PredictMDx for Glioblastoma can help identify patients that are likely to respond to the most commonly used class of brain cancer drugs (alkylating agents).
    
    About MDxHealth®
    
20. [verwijderd] 28 april 2014 14:44

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Sumitomo Japan license ( redelijk recent )
    
    Press Release
    MDxHealth and Sumitomo Sign Pharmaco Molecular Diagnostic Partnership for Japan
    
    IRVINE, CA, and LIEGE, BELGIUM - 8:00 AM, July 1, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, today announced the signing of a partnership with Summit Pharmaceuticals International Corporation (SPI) a subsidiary of Sumitomo Corporation to gain access to the Japanese market with its pharmaco molecular diagnostic (PharmacoMDx) epigenetic technologies and products. Expanding upon MDxHealth's PharmacoMDx program, the partnership aims to provide companion diagnostic solutions, or theranostics, to pharmaceutical companies in the Japanese market. No financial terms have been disclosed.
    
    "As the global life sciences industry continues to pair diagnostics with therapeutics to determine patient response, we believe this partnership with SPI will provide MDxHealth with the necessary leverage and expertise to penetrate the Japanese market," stated Dr. Jan Groen, CEO of MDxHealth. "We look forward to working closely with the SPI team to offer our unique epigenetic PharmacoMDx products and services to drug development companies."
    
    MDxHealth's PharmacoMDx team leverages Next-Generation and Deep Sequencing technologies for the identification and validation of powerful epigenetic biomarkers for novel therapeutics. Companion diagnostic assays are playing an increasingly important role in the development process of new compounds as they can help identify patients who may benefit from a new drug, improving efficacy, reducing adverse side effects, and potentially accelerating regulatory approval thereby helping pharma companies reduce the time and cost associated with bringing new products to market.
    
    About Summit Pharmaceuticals International Corporation
    Summit Pharmaceuticals International Corporation is a group of specialists in Japan that provides high-quality integrated services from drug discovery research to the production stage of pharmaceuticals and chemicals. SPI is a subsidiary of Sumitomo Corporation which is a leading general trading company with 140 locations in 66 countries throughout the world. For more information, visit www.summitpharma.co.jp/.
    
    About MDxHealth®
    MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The company's first commercial product, ConfirmMDxTM for Prostate Cancer, has been shown to help distinguish patients who have a true-negative biopsy from those who may have undetected cancer. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for prostate, brain and lung cancers. The company is based in Irvine, California with a European headquarters in Liege, Belgium. For more information visit MDxHealth's website at www.mdxhealth.co